Vaccines

Drs. Jason Lee and John J. Russell discuss the impact of chronic health conditions on adults.

Vaccine experts discuss racial disparities and the impact on influenza vaccinations.

Four for adult vaccines effective immediately, four pending approval for youths.

Jason Lee, M.S., Ph.D.(c), and John J. Russell, M.D., address vaccine hesitancy and gaps in influenza vaccines in adults.

Jason Lee, M.S., Ph.D.(c), discusses results and takeaways from the study of a high-dose influenza vaccine in older adults.

Company claims rivals copied proprietary mRNA technology to make shots.

Jason Lee, M.S., Ph.D.(c), discusses the rationale, objectives, and methods for a study of the efficacy and effectiveness of a high-dose influenza vaccine in older adults.

Jason Lee, M.S., Ph.D.(c), discusses the background to seasonal influenza.

Back-to-school season is prime time to reach parents and children about immunizations.

Codes enable billing for lab tests, administering vaccines

The pandemic underscored the incredible power of vaccination.

The move will delay the vaccine’s authorization for this younger group.

An EUA for the smaller shots would plug a hole in the nation’s vaccination strategy.

Spikevax is now the second COVID-19 vaccine approved by US regulators.

The company says a third dose of their COVID-19 vaccine is effective against the latest variant of the disease.

Nearly a third of hospital personnel had still not been vaccinated against COVID-19 by mid-September.

The move comes just in time for the holiday travel season.

The administration is also reportedly planning on purchasing millions of doses of the company’s antiviral pill.

The company is asking the FDA to make the additional shots available to anyone 18 years old or older.

Wrangling over the requirement continues in the courts.

After a panel federal judges put a temporary halt on the mandate, the U.S. Surgeon General says the administration is ready to fight for the requirement.

The regulation would affect more than 17 million healthcare workers.

The agency moved quickly to approve the smaller shots.

The vaccine is just awaiting a recommendation from the CDC before they can be rolled out.

A previous analysis found the vaccine was 90.7 percent effective against severe COVID-19.

The FDA is expected to act on an EUA application for the smaller doses next week.

The administration sees pediatricians and primary care physicians taking the lead in the push.

The agency is expected to decide on that as well as Moderna and Johnson and Johnson boosters this week.

The advisory panel is also scheduled to discuss Merck antiviral pill late next month.

A recommendation is expected on whether the shot should be authorized.